![Ranjan Batra](https://cdn.asp.events/CLIENT_HubXchan_638DBA0F_0C6E_8D3C_A444829FC0C4B73E/sites/HubXChange/media/libraries/speakers/RANJAN-1.jpg/fit-in/500x500/filters:no_upscale())
![](https://cdn.asp.events/CLIENT_HubXchan_638DBA0F_0C6E_8D3C_A444829FC0C4B73E/sites/HubXChange/media/libraries/experts/Lexeo-Therapeutics.png)
Ranjan Batra
Vice President, Discovery, Research and Translation,
Lexeo Therapeutics
Ron is a co-founder and joined Locanabio full-time in March 2018. Ron serves as Senior Vice President, Research and Development and was a significant contributor to the foundational work of RNA-targeting CRISPR therapeutics for microsatellite expansion diseases. Prior to joining Locanabio, Ron worked at Verily. Ron is an expert in RNA splicing and development of therapeutics of RNA-mediated diseases. He was awarded the Myotonic Dystrophy Foundation (MDF) postdoctoral fellowship for his work at the laboratory of Gene Yeo PhD at UC San Diego. During his time at UC San Diego, he also worked with the department of Neurology, studying pathology and disease mechanisms of neuromuscular diseases. Prior to UC San Diego, Ron completed his PhD degree in Genetics at University of Florida where he studied RNA biology and gene therapy of neuromuscular diseases. Ron was awarded the 2019 Biocom Catalyst award for biotech leaders under 40 in California, and was a finalist for Endpoints News’ “20 under 40” biopharma leaders in 2021 and top 25 health care leaders in San Diego by The Healthcare Technology Report in 2022. Ron has published more than 25 papers and patents in RNA biology and RNA therapeutics.